Lv2
200 积分 2023-11-10 加入
Characterizing the antibody response to amustaline/glutathione pathogen‐reduced red blood cells
7个月前
已完结
Genetic background of anti‐CD99 producers in Japan and analysis of hemolytic transfusion reactions due to anti‐CD99
7个月前
已完结
Therapeutic efficacy and safety of pathogen‐reduced platelet components: Results of a meta‐analysis of randomized controlled trials
7个月前
已完结
Assessing the inactivation capabilities of two commercially available platelet component pathogen inactivation systems: effectiveness at end of shelf life
8个月前
已完结
The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets
8个月前
已完结
Bacterial inactivation of platelet concentrates with the THERAFLEX UV‐Platelets pathogen inactivation system
8个月前
已完结
Challenge study of the pathogen reduction capacity of the THERAFLEX MB-Plasma technology
8个月前
已完结
Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non‐leucoreduced platelet‐rich plasma‐derived platelets suspended in plasma
8个月前
已完结
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
10个月前
已完结
皖公网安备34019202002308
